Novel in vitro method reveals drugs that inhibit solute transporter alpha/beta
Self archived versionfinal draft
MetadataShow full item record
CitationMalinen, Melina M. Kauttonen, Antti. Beaudoin, James J. Sjöstedt, Noora. Honkakoski, Paavo. Brouwer, Kim LR. (2019). Novel in vitro method reveals drugs that inhibit solute transporter alpha/beta. Molecular Pharmaceutics, 16 (1) , 238-246. 10.1021/acs.molpharmaceut.8b00966.
Drug interactions with the organic solute transporter alpha/beta (OSTα/β) are understudied even though OSTα/β is an important transporter that is expressed in multiple human tissues including the intestine, kidneys, and liver. In this study, an in vitro method to identify novel OSTα/β inhibitors was first developed using OSTα/β-overexpressing Flp-In 293 cells. Incubation conditions were optimized using previously reported OSTα/β inhibitors. A method including a 10 min preincubation step with the test compound was used to screen for OSTα/β inhibition by 77 structurally diverse compounds and fixed-dose combinations. Seven compounds and one fixed-dose combination (100 μM final concentration) inhibited OSTα/β-mediated dehydroepiandrosterone sulfate (DHEAS) uptake by >25%. Concentration-dependent OSTα/β inhibition was evaluated for all putative inhibitors (atorvastatin, ethinylestradiol, fidaxomicin, glycochenodeoxycholate, norgestimate, troglitazone, and troglitazone sulfate). Ethinylestradiol, fidaxomicin, and troglitazone sulfate yielded a clear concentration–inhibition response with IC50 values <200 μM. Among all tested compounds, there was no clear association between physicochemical properties, the severity of hepatotoxicity, and the degree of OSTα/β inhibition. This study utilized a novel in vitro method to identify OSTα/β inhibitors and, for the first time, provided IC50 values for OSTα/β inhibition. These data provide evidence that several drugs, some of which are associated with cholestatic drug-induced liver injury, may impair the function of the OSTα/β transporter.
Subjectsbasolateral efflux bile acid cholestasis drug-induced liver injury inhibition SLC51A/B
Link to the original itemhttp://dx.doi.org/10.1021/acs.molpharmaceut.8b00966
PublisherAmerican Chemical Society (ACS)
- Terveystieteiden tiedekunta